# InventisBio Co., Ltd clinical trials: 34 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 34 trials with InventisBio Co., Ltd as lead sponsor, 11 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by InventisBio Co., Ltd: 34 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/inventisbio-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 34
- Recruiting or not yet: 11
- Read on: November 19, 2026

## Trials

The 25 newest of 34, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 15, 2026 | NCT07875842 | A Phase I Study of the Interaction of D-2570 With Other Drugs in Healthy Adults | InventisBio Co., Ltd | Phase 1 | Not yet recruiting | Healthy Subjects | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875842) |
| September 9, 2026 | NCT07809607 | A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors | InventisBio Co., Ltd | Phase 1 | Not yet recruiting | Advanced Solid Tumor Cancer | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809607) |
| July 20, 2026 | NCT07715175 | The Study is to Investigate D-2570 in Participants With Different Levels of Kidney Function. | InventisBio Co., Ltd | Phase 1 | Recruiting | Renal Impairment | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715175) |
| July 20, 2026 | NCT07715149 | A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function | InventisBio Co., Ltd | Phase 1 | Recruiting | Healthy Adult Participants, Hepatic Impairment (HI) | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715149) |
| June 4, 2026 | NCT07625891 | Study of D-2570 in Subjects With Non-Segmental Vitiligo | InventisBio Co., Ltd | Phase 2 | Recruiting | Vitiligo, Non-Segmental Vitiligo (NSV) | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625891) |
| March 24, 2026 | NCT07489885 | A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis | InventisBio Co., Ltd | Phase 2 | Recruiting | Psoriasis | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07489885) |
| February 17, 2026 | NCT07411742 | Mass Balance Study of \[14C\] D-2570 | InventisBio Co., Ltd | Phase 1 | Active not recruiting | Mass Balance Study | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07411742) |
| January 8, 2026 | NCT07326813 | A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis | InventisBio Co., Ltd | Phase 3 | Recruiting | Plaque Psoriasis | 477 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07326813) |
| January 2, 2026 | NCT07315061 | A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis | InventisBio Co., Ltd | Phase 2 | Recruiting | PsA (Psoriatic Arthritis) | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07315061) |
| December 30, 2025 | NCT07311200 | A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) | InventisBio Co., Ltd | Phase 2 | Recruiting | Active Systemic Lupus Erythematosus | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07311200) |
| December 10, 2025 | NCT07275775 | Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Tablets in Healthy... | InventisBio Co., Ltd | Phase 1 | Completed | Healthy | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07275775) |
| December 8, 2025 | NCT07270783 | Healthy Volunteer Study | InventisBio Co., Ltd | Phase 1 | Active not recruiting | Healthy Volunteer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07270783) |
| August 19, 2025 | NCT07130604 | Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis | InventisBio Co., Ltd | Phase 3 | Recruiting | Plaque Psoriasis | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07130604) |
| June 24, 2025 | NCT07035041 | A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis | InventisBio Co., Ltd | Phase 2 | Active not recruiting | UC - Ulcerative Colitis, Moderately to Severely Active Ulcerative Colitis | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07035041) |
| May 2, 2025 | NCT06954961 | A Study to Evaluate D-0502 in Subjects With ER+ Her2- Locally Advanced or Metastatic Breast Cancer | InventisBio Co., Ltd | Phase 3 | Recruiting | Breast Cancer | 640 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06954961) |
| February 26, 2024 | NCT06278350 | Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis | InventisBio Co., Ltd | Phase 2 | Completed | Plaque Psoriasis | 161 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06278350) |
| January 31, 2024 | NCT06233916 | Mass Balance Study of \[14C\] D-1553 in Chinese Healthy Adult Male Subjects | InventisBio Co., Ltd | Phase 1 | Completed | Mass Balance Study | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06233916) |
| October 27, 2023 | NCT06105255 | A Study to Evaluate the Effects of D-1553 on PK of Midazolam, Caffeine, Rosuvastatin, Furosemide, Digoxin, and Itraconazole or Omeprazole... | InventisBio Co., Ltd | Phase 1 | Completed | Healthy Male | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06105255) |
| December 27, 2022 | NCT05665699 | Phase II Study to Evaluate Efficacy and Safety of D-0120 in Combination With Allopurinol in Subjects With Gout | InventisBio Co., Ltd | Phase 2 | Completed | Gout | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05665699) |
| August 17, 2022 | NCT05504083 | Evaluate the Efficacy and Safety of D-0120 in Primary Hyperuricemia Patients | InventisBio Co., Ltd | Phase 2 | Completed | Hyperuricemia | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05504083) |
| August 8, 2022 | NCT05492045 | A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer | InventisBio Co., Ltd | Phase 1/2 | Terminated | NSCLC | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05492045) |
| May 20, 2022 | NCT05383898 | Study to Evaluate D-1553 in Subjects With Lung Cancer | InventisBio Co., Ltd | Phase 1/2 | Completed | NSCLC | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05383898) |
| May 18, 2022 | NCT05379946 | Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors | InventisBio Co., Ltd | Phase 1/2 | Active not recruiting | Solid Tumor | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05379946) |
| May 4, 2022 | NCT05360628 | Evaluation of PK and Safety of D-0120 and Allopurinol | InventisBio Co., Ltd | Early phase 1 | Completed | Healthy | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05360628) |
| April 21, 2022 | NCT05339633 | Study in Healthy Adult Female Subjects | InventisBio Co., Ltd | Phase 1 | Completed | Mass Balance Recovery | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05339633) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 16 |
| Phase 1/2 | 5 |
| Phase 2 | 9 |
| Phase 3 | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 17 |
| Recruiting | 9 |
| Active not recruiting | 4 |
| Not yet recruiting | 2 |
| Unknown | 1 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Breast Neoplasms | 3 |
| Gout | 3 |
| Hyperuricemia | 2 |
| Colitis, Ulcerative | 1 |
| Psoriasis | 1 |
| Arthritis, Psoriatic | 1 |
| Vitiligo | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Apparel manufacturers in the United States](https://specstream.ai/data/businesses/apparel-manufacturers/united-states)
- [Environmental services in the United States](https://specstream.ai/data/businesses/environmental-services/united-states)
- [Optical wholesalers in the United States](https://specstream.ai/data/businesses/optical-wholesalers/united-states)
- [Water purification companies in the United States](https://specstream.ai/data/businesses/water-purification-companies/united-states)
- [Dialysis clinics in the United States](https://specstream.ai/data/businesses/dialysis-clinics/united-states)
- [Mechanical engineering firms in the United States](https://specstream.ai/data/businesses/mechanical-engineering-firms/united-states)
